Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Tolerance of D-Gam vs Rhophylac in Rh-D-negative Healthy Volunteers
NCT02246842Phase 1Completed
- Sponsor
- Bio Products Laboratory
- Start
- May 2004
- Primary completion
- Dec 2004
- Modality
- Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised trial of rho(d) immune globulin in RhD alloimmunization (2 arms), sponsored by Bio Products Laboratory. Primary endpoint: Maximum Serum Concentration at 14 weeks. Started May 2004; status: completed.
02
Drugs
rho(d) immune globulin
03
Conditions
RhD alloimmunization
Beyond the preview
Go deeper on NCT02246842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02246842.